Tau mutations as a novel risk factor for cancer—letter

the LEFFTDS Consortium

doi:10.1158/0008-5472.CAN-18-2313

Tau mutations as a novel risk factor for cancer—letter

the LEFFTDS Consortium

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	6523-6524
Number of pages	2
Journal	Cancer research
Volume	78
Issue number	22
DOIs	https://doi.org/10.1158/0008-5472.CAN-18-2313
State	Published - Nov 15 2018

Access to Document

10.1158/0008-5472.CAN-18-2313

Cite this

@article{abde7e846b3b4c13a781fc0698ef7732,

title = "Tau mutations as a novel risk factor for cancer—letter",

author = "{the LEFFTDS Consortium} and Deutschl{\"a}nder, {Angela B.} and Boeve, {Bradley F.} and Rosen, {Howard J.} and Boxer, {Adam L.} and Wszolek, {Zbigniew K.} and Danielle Brushaber and Giovanni Coppola and Bradford Dickerson and Jamie Fong and Tatiana Foroud and Leah Forsberg and Ralitza Gavrilova and Nupur Ghoshal and Jill Goldman and Jon Graff-Radford and Neill Graff-Radford and Murray Grossman and Heuer, {Hilary W.} and Hsiung, {Ging Yuek R.} and Huey, {Edward D.} and David Irwin and David Jones and Kejal Kantarci and Anna Karydas and David Knopman and John Kornak and Joel Kramer and Walter Kremers and Walter Kukull and Maria Lapid and Diane Lucente and Ian Mackenzie and Scott McGinnis and Bruce Miller and Len Petrucelli and Rosa Rademakers and Ramos, {Eliana M.} and Katherine Rankin and Katya Rascovsky and Les Shaw and Jeremy Syrjanen and Joanne Taylor and Arthur Toga and John Trojanowski and Sandra Weintraub and Bonnie Wong",

note = "Funding Information: The LEFFTDS study is supported by the following NIH grants: U01 AG045390-01A1, U54 NS092089, U24 AG021886, U01 AG016976, and P50 NS072187 (to B. Boeve, H. Rosen, A. Boxer, and Z.K. Wszolek). Funding Information: A.B. Deutschl€ander reports receiving a commercial research grant from Allergan Educational Grant. H.J. Rosen reports receiving a commercial research grant from Biogen Pharmceuticals and is a consultant/advisory board member for Ionis Pharmaceuticals and Wave Pharmaceuticals. A.L. Boxer reports receiving a commercial research grant from Genentech, Roche, Biogen, BMS, Lilly and has ownership interest (including stocks and patents) in Alector, Aeton Therapeutics. He is a consultant/advisory board member for Abbvie, Arkuda, Merck, Novartis, Samumed, Toyama, UCB, Asceneuro, and Wave. No potential conflicts of interest were disclosed by the other authors.",

year = "2018",

month = nov,

day = "15",

doi = "10.1158/0008-5472.CAN-18-2313",

language = "English",

volume = "78",

pages = "6523--6524",

journal = "Cancer research",

issn = "0008-5472",

number = "22",

}

TY - JOUR

T1 - Tau mutations as a novel risk factor for cancer—letter

AU - the LEFFTDS Consortium

AU - Deutschländer, Angela B.

AU - Boeve, Bradley F.

AU - Rosen, Howard J.

AU - Boxer, Adam L.

AU - Wszolek, Zbigniew K.

AU - Brushaber, Danielle

AU - Coppola, Giovanni

AU - Dickerson, Bradford

AU - Fong, Jamie

AU - Foroud, Tatiana

AU - Forsberg, Leah

AU - Gavrilova, Ralitza

AU - Ghoshal, Nupur

AU - Goldman, Jill

AU - Graff-Radford, Jon

AU - Graff-Radford, Neill

AU - Grossman, Murray

AU - Heuer, Hilary W.

AU - Hsiung, Ging Yuek R.

AU - Huey, Edward D.

AU - Irwin, David

AU - Jones, David

AU - Kantarci, Kejal

AU - Karydas, Anna

AU - Knopman, David

AU - Kornak, John

AU - Kramer, Joel

AU - Kremers, Walter

AU - Kukull, Walter

AU - Lapid, Maria

AU - Lucente, Diane

AU - Mackenzie, Ian

AU - McGinnis, Scott

AU - Miller, Bruce

AU - Petrucelli, Len

AU - Rademakers, Rosa

AU - Ramos, Eliana M.

AU - Rankin, Katherine

AU - Rascovsky, Katya

AU - Shaw, Les

AU - Syrjanen, Jeremy

AU - Taylor, Joanne

AU - Toga, Arthur

AU - Trojanowski, John

AU - Weintraub, Sandra

AU - Wong, Bonnie

N1 - Funding Information: The LEFFTDS study is supported by the following NIH grants: U01 AG045390-01A1, U54 NS092089, U24 AG021886, U01 AG016976, and P50 NS072187 (to B. Boeve, H. Rosen, A. Boxer, and Z.K. Wszolek). Funding Information: A.B. Deutschl€ander reports receiving a commercial research grant from Allergan Educational Grant. H.J. Rosen reports receiving a commercial research grant from Biogen Pharmceuticals and is a consultant/advisory board member for Ionis Pharmaceuticals and Wave Pharmaceuticals. A.L. Boxer reports receiving a commercial research grant from Genentech, Roche, Biogen, BMS, Lilly and has ownership interest (including stocks and patents) in Alector, Aeton Therapeutics. He is a consultant/advisory board member for Abbvie, Arkuda, Merck, Novartis, Samumed, Toyama, UCB, Asceneuro, and Wave. No potential conflicts of interest were disclosed by the other authors.

PY - 2018/11/15

Y1 - 2018/11/15

UR - http://www.scopus.com/inward/record.url?scp=85056606062&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2313

DO - 10.1158/0008-5472.CAN-18-2313

M3 - Letter

C2 - 30373809

AN - SCOPUS:85056606062

SN - 0008-5472

VL - 78

SP - 6523

EP - 6524

JO - Cancer research

JF - Cancer research

IS - 22

ER -

Tau mutations as a novel risk factor for cancer—letter

Access to Document

Other files and links

Cite this